Notice of Intent (NOI) to Sole Source to Optum Pharmacy Inc. Hazardous Drug Compounding Services

NOTICE OF INTENT TO AWARD SOLE SOURCE I. The Network Contracting Office (NCO) 16, located at Galleria Financial Center, 5075 Westheimer Rd, Ste 750, Houston, TX 77056 in support of Central Arkansas Veterans Health Care System (CAVHCS), intends to solicit and award Sole Source, Firm-Fixed-Price, Blanket Purchase Agreement (BPA) to one Large Business source, Optum Pharmacy Inc. Optum Pharmacy Inc. 23620 N 20TH Drive Suite 12 Phoenix, AZ 85085 CAVHCS has a requirement for compounding hazardous chemotherapy agents for its Little Rock campus. These compounding services are necessary to provide chemotherapy treatments to Veterans diagnosed with specific medical conditions. CAVHS has approximately 10 12 patients on any given day Monday Friday for Chemotherapy Infusion. Compounding must be done at an FDA 503A compliant facility and meet all state and federal laws. Contractor shall provide all chemotherapy agents, IV Tubing, closed system drug transfer devices, and any other items deemed necessary. All Hazardous Chemotherapy Agents will be aseptically compounded based on patient specific orders. II. The North American Industry Classification (NAICS) code for this acquisition is 325412, Electronic and Precision Equipment Repair and Maintenance. Size Standard 1300. III. This procurement is being conducted under Federal Acquisition Regulation (FAR) Parts 12 and 13.5 in accordance with (IAW) FAR Part 13.106-1(b) Soliciting from a single source. IV. The anticipated award date is November 1, 2025. The Government intends to award a Firm-Fixed-Price Blanket Purchase Agreement (BPA). V. Please note that this is not a request for competitive quotes and is being posted for informational purposes only. The government does not anticipate receiving responses to this notice. However, interested parties who disagree with this action may submit a letter of interest that demonstrates your firm s technical capability to provide all chemotherapy agents, IV Tubing, closed system drug transfer devices, and any other items deemed necessary. All Hazardous Chemotherapy Agents will be aseptically compounded based on patient specific orders. The contractor shall communicate its technical capability, provide current pharmacy registration/license, courier license/certification to provide the services required per this notice and draft statement of work (SOW). The government reserves the right to verify any request for additional documentation submitted. VI. Interested parties shall identify their interests, provide certifications/licenses as mentioned in section V of this document and capability to meet the government requirements and respond to this notice within fifteen (15) calendar days of the publication of this notice. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government. Interested parties may identify their interest solely via email to Contracting Officer, Anthony Marion, Anthony.marion2@va.gov no later than September 18, 2025, 10:00am Central Standard Time (CST). When responding to this announcement, respondents should include 36C25625Q1457 Notice of Intent" in the subject line. VII. Late responses may not be accepted. No telephone inquiries will be accepted nor will phone calls be returned. Only emailed responses will be considered. The information received will be utilized solely for determining whether to conduct competitive procurement. A determination not to compete this proposed acquisition based upon responses to this notice is at the sole discretion of the Government.